A peek at Sio Gene Therapies Inc. (SIOX): Who has invested in It?

59 institutions hold shares in Sio Gene Therapies Inc. (SIOX), with 22.66M shares held by insiders accounting for 38.58% while institutional investors hold 40.70% of the company’s shares. The shares outstanding are 46.73M, and float is at 40.05M with Short Float at 2.34%. Institutions hold 25.00% of the Float.

The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Consonance Capital Management LP with over 3.24 million shares valued at $14.95 million. The investor’s holdings represent 6.68% of the SIOX Shares outstanding. As of Sep 29, 2020, the second largest holder is Opaleye Management Inc. with 2.04 million shares valued at $9.42 million to account for 4.21% of the shares outstanding. The other top investors are Hudson Bay Capital Management LP which holds 1.32 million shares representing 2.73% and valued at over $6.12 million, while Sphera Funds Management Ltd holds 2.38% of the shares totaling 1.15 million with a market value of $5.33 million.

Sio Gene Therapies Inc. (NASDAQ: SIOX) is 9.35% higher on its value in year-to-date trading and has touched a low of $1.41 and a high of $5.74 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SIOX stock was last observed hovering at around $3.15 in the last trading session, with the day’s loss setting it -0.11% off its average median price target of $8.00 for the next 12 months. It is also 62.0% off the consensus price target high of $8.00 offered by 4 analysts, but current levels are 56.57% higher than the price target low of $7.00 for the same period.

Currently trading at $3.04, the stock is 2.36% and 4.88% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.46 million and changing -3.49% at the moment leaves the stock -2.13% off its SMA200. SIOX registered -31.84% loss for a year compared to 6-month loss of -6.75%. The firm has a 50-day simple moving average (SMA 50) of $2.9682 and a 200-day simple moving average (SMA200) of $3.0876.

The stock witnessed a 5.56% gain in the last 1 month and extending the period to 3 months gives it a 33.92%, and is -8.16% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.48% over the week and 9.06% over the month.

Distance from 52-week low is 115.60% and -47.04% from its 52-week high.

Sio Gene Therapies Inc. (SIOX) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Sio Gene Therapies Inc. (SIOX) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 1.80, where 1 rate it as a Hold and 1 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Sio Gene Therapies Inc. is expected to release its quarterly report on 06/15/2021 and quarterly earnings per share for the current quarter are estimated at -$0.22.The EPS is expected to grow by 63.50% this year.

Sio Gene Therapies Inc. (SIOX) Insider Activity

A total of 1 insider transactions have happened at Sio Gene Therapies Inc. (SIOX) in the last six months, with sales accounting for 0 and purchases happening 1 times. The most recent transaction is an insider purchase by Pande Atul, the company’s Director. SEC filings show that Pande Atul bought 10,000 shares of the company’s common stock on Nov 24 at a price of $2.34 per share for a total of $23399.0. Following the purchase, the insider now owns 33370.0 shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free